Addressing Specialty and Orphan Drugs

「In addition to investing in イシンファーマ株式会社 in May 2025 and サーブ・バイオファーマ株式会社 in January 2026, the company advanced the development of a full-line service for specialty products by launching L1MON, a home-delivery service for specialty products.」

「For specialty products, which are expected to grow in the future, we continue to expand our full-line services, providing domestic and overseas pharmaceutical manufacturers with an integrated range of services from research and development through manufacturing and distribution. In July, we entered into business alliances with 帝人リジェネット株式会社 and 伊藤忠商事株式会社 and began building a Regenerative Medicine Ecosystem, under which the three companies provide one-stop support for the services required to bring regenerative medicine products to market. As a first step, in September we jointly held the Regenerative Medicine Top Runner Seminar with both companies for pharmaceutical manufacturers and drug-discovery ventures.」

「With a view to the growth of specialty products, which are expected to become a mainstream segment of the pharmaceutical market, we entered into a capital and business alliance with ワコン株式会社, which manufactures and sells logistics equipment, including temperature-controlled containers for pharmaceuticals.」

「To begin handling regenerative medicine products, which are expected to drive future market growth, and to establish a system for proper distribution, we newly established the Regenerative Medicine Management Office within 東邦薬品株式会社.」

「In addition, sales of products with restricted wholesale distribution, including specialty pharmaceuticals, continued to grow steadily,」

「In the pharmaceutical wholesaling business, sales of products with restricted wholesale distribution, including specialty pharmaceuticals, grew steadily and made a substantial contribution to sales.」

「In addition, recognizing our Group's advanced logistics system, its ability to respond in emergencies and its track record in contract operations, レオ ファーマ株式会社 entrusted us with distribution operations, beginning in January 2023, for Dovonex® Ointment 50μg/g, a treatment for plaque psoriasis that レオ ファーマ株式会社 began selling directly.」

「In the pharmaceutical wholesaling business, sales of products with restricted wholesale distribution, including specialty pharmaceuticals, grew steadily and made a substantial contribution to sales.」

「In addition, recognizing the capabilities of our Group's advanced logistics system, its ability to respond in emergencies and its track record in contract operations, we have been entrusted with distribution operations for TREAKSIS®, an antineoplastic agent manufactured by シンバイオ製薬株式会社, since 10 December 2020.」

「The company performed solidly, supported by growth in sales of new drugs such as cancer treatments, specialty pharmaceuticals and orphan drugs, as well as the expansion of contracts for customer support systems, including the new-patient registration service.」

「Although the company was affected by drug price revisions, performance remained steady, supported by growth in sales of new drugs such as cancer treatments, specialty pharmaceuticals and orphan drugs, as well as the expansion of customer support systems, including the new-patient registration service.」

「At the company, too, sales revenue, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all significantly exceeded the initial plan, due in part to growth in sales of new drugs such as cancer treatments, specialty pharmaceuticals and orphan drugs, as well as the expansion of customer support systems.」

「In addition, the company reached a basic agreement with 株式会社スズケン in July 2018 on the joint use of customer support systems, and in February 2019 on the joint development of a new distribution model for generic and specialty pharmaceuticals.」

「Although new drugs, including anticancer drugs, contributed, growth was substantially negative compared with the previous year.」

「In the pharmaceutical wholesaling business, new drugs, including anticancer drugs, contributed to performance, but the business was affected by drug price revisions, the expansion of generic drugs, and the contraction of the hepatitis C treatment market, which had grown rapidly since the second quarter of the previous fiscal year.」

「Sales of hepatitis C treatments and contributions from new drugs, including anticancer drugs, supported performance.」

「The expansion in year-on-year comparisons of the hepatitis C treatment, which grew rapidly from last autumn, and growth in new medicines such as anticancer drugs」

「We will seek to expand our customer base by exploring untapped segments through the handling of specialty drugs, orphan drugs, and other pharmaceuticals requiring advanced management, as well as healthcare-related services and the development of new business models.」